William J. Link PhD - 16 Jun 2022 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Reporting relationship: Director
Issuer ticker: TARS
Reported as of: 16 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Jul 2022, 12:28:21 UTC
Prior SEC filing: 09 Jun 2022
Next SEC filing: 11 Aug 2022
Source filing: View source filing
Reporting owner signature: /s/ Leonard M. Greenstein

Key filing fact

William J. Link PhD filed Form 4 for Tarsus Pharmaceuticals, Inc. (TARS) on 01 Jul 2022.

Key facts

This page summarizes William J. Link PhD's Form 4 filing for Tarsus Pharmaceuticals, Inc. (TARS).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 01 Jul 2022, 12:28.

Change

Previous filing in this sequence was filed on 09 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TARS transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +7,000
Change %
Price: $0.000000
Shares after: 7,000
Date: 16 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,000
Exercise price: $12.89
Footnotes: F1

TARS transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +2,000
Change %
Price: $0.000000
Shares after: 2,000
Date: 16 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,000
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2022 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Footnote F2

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

Footnote F3

RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2022 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.